If you have been living with PCOS, or if you have spent years suspecting something was wrong with your hormones, your metabolism, your cycle, and your body, only to leave appointments with more questions than answers, this week’s news matters for you. The PCOS’s new name, PMOS, became official on May 12, 2026. And at Diverse Health, we think this is one of the most important shifts in women’s healthcare in a generation.
This is not just a medical rebrand. It is a reckoning with how the condition was misnamed, misunderstood, and mismanaged for decades. And it opens a door to something millions of women have never had: a diagnosis that actually tells the truth about what is happening in their bodies.
What exactly changed?
On May 12, 2026, a landmark global consensus paper was published in The Lancet, officially renaming polycystic ovary syndrome (PCOS) to Polyendocrine Metabolic Ovarian Syndrome — PMOS. The name change was the result of 14 years of global collaboration spanning 56 leading academic, clinical, and patient organizations, and more than 22,000 survey responses from patients and healthcare professionals across every world region.
The conclusion was unanimous: the old name was harming. As the authors wrote in The Lancet, the term PCOS was “inaccurate, implying pathological ovarian cysts, obscuring diverse endocrine and metabolic features, and contributing to delayed diagnosis, fragmented care, and stigma, while curtailing research and policy framing.”
The new name, PMOS, is built to fix all of that. It was presented simultaneously at the European Congress of Endocrinology in Prague and is now being adopted across clinical guidelines, medical education, and international disease classification systems worldwide.
Why the old name was a problem, and who paid the price
Say “polycystic ovary syndrome” and most people, including many providers, immediately think: ovarian cysts. But here is what the science has shown for years: cysts are not actually a defining feature of the condition. You can have PCOS, now PMOS, without a single cyst visible on an ultrasound. And you can have cysts and not have PMOS at all.
Because the name pointed to the wrong thing, providers focused on the wrong thing. Women who did not present with visible ovarian cysts were dismissed, even while experiencing irregular periods, severe metabolic disruption, fertility struggles, weight changes, skin symptoms, and significant mental health impacts. The name created a narrow door that too many women could not walk through.
1 in 8 women worldwide are affected by PMOS, more than 170 million people. 70% of those affected remain undiagnosed, according to the WHO
Those numbers are not a coincidence. They are the direct consequence of a condition that was misnamed, misframed, and under-resourced for decades. As Dr. Alla Vash-Margita of Yale University told ABC News:
“By calling this condition polycystic ovary, we’re missing the big picture. There was a lot of stigma and myth related to this name.”
What PMOS actually is — the full picture
PMOS is not a reproductive condition with some metabolic side effects. It is a complex, multisystem hormonal disorder that affects the endocrine, metabolic, and reproductive systems, skin health, and mental health, simultaneously and interconnectedly.
The new name reflects this accurately. “Polyendocrine” acknowledges that multiple hormones are involved, not just ovarian hormones. “Metabolic” acknowledges that the condition carries significant cardiometabolic risk. And “Ovarian” remains because the ovaries are still one part of the clinical picture, but only one part.
What this means in practice is that PMOS can show up as:
- Irregular, absent, or painful periods
- Difficulty getting pregnant
- Insulin resistance and increased risk of type 2 diabetes
- Weight changes that are resistant to a standard diet and exercise
- Elevated androgens, causing acne, hair thinning, or excess body hair
- Cardiovascular disease risk, including hypertension
- Anxiety, depression, and other mental health conditions
- Chronic fatigue and pain
Two women with PMOS can have completely different symptom profiles, and both are valid. That range was part of what the old name failed to capture.
Why does this matter more for Black and Brown women
The renaming of PCOS to PMOS is a medical milestone. But for Black and Brown women in the United States, the stakes of this conversation are higher, and the history is harder.
Research published in peer-reviewed journals has consistently shown that while PMOS occurs at similar rates across racial groups, Black and Hispanic women are significantly more likely to experience more severe metabolic complications — including higher rates of insulin resistance, hypertension, and cardiovascular risk. Yet they are less likely to receive an early diagnosis.
That gap is not a biological destiny. It is the product of a healthcare system where Black women’s symptoms are more frequently dismissed, where pain and metabolic distress are less often flagged for follow-up, and where the narrow, cyst-focused definition of the old name made it even easier to overlook presentations that did not match the textbook picture.
According to one large-scale study, disparities in healthcare access and cultural sensitivity contribute directly to delayed diagnosis and suboptimal treatment in minority women, increasing their long-term vulnerability to conditions like type 2 diabetes and cardiovascular disease, which PMOS already raises the risk of.
PMOS, by broadening the clinical definition and naming the metabolic reality of the condition, creates an opportunity to catch what was being missed. But a better name alone will not close that gap. Culturally competent providers who listen, test thoroughly, and take the whole picture seriously are what will.
What the name change means for diagnosis and treatment going forward
The renaming of PMOS is not cosmetic. According to the University of Colorado Anschutz Medical Campus, the reclassification will trigger updates to clinical guidelines, medical education curricula, and international disease classification systems — meaning how providers are trained to recognize, diagnose, and treat this condition is changing at the foundation.
In practice, this means:
- Providers will be expected to assess the full hormonal and metabolic picture — not just look for cysts on an ultrasound
- Diagnostic criteria will better reflect the wide range of presentations, reducing the chance of dismissal for patients who do not present in the “classic” way
- Research funding and policy framing will expand beyond a reproductive lens to include cardiometabolic outcomes
- Patients will have a name for their condition that they can use to communicate across specialties without being told their symptoms do not fit
As Dr. Cree, director of the Multi-Disciplinary PCOS Clinic at Children’s Hospital Colorado, put it: “Language matters in medicine. The previous name often led to misconceptions and stigma, particularly around fertility. This change helps shift the conversation toward overall health rather than a single aspect of the condition.”
How Diverse Health supports women with PMOS
At Diverse Health, we have always treated women’s health as more than reproductive health. And the renaming of PCOS to PMOS confirms exactly what we have built our care model around: that hormonal conditions are whole-body conditions, and that women deserve providers who understand that.
For women living with PMOS, care should never be fragmented. You should not have to see one provider for your irregular cycles, another for your insulin resistance, another for your mental health, and fight at every step to have each specialist understand the full picture. That fragmentation is part of what the old name created, and it is what Diverse Health is designed to address. mydiversehealth.com/ourservices
Our virtual care model provides:
- Primary care that takes your full hormonal and metabolic history seriously from appointment one
- Women’s health services that go beyond cycles and fertility to address PMOS comprehensively
- Mental health support — because anxiety, depression, and mood changes are not side effects to brush past, they are part of the condition
- Medication management for the insulin resistance, hormonal imbalance, and metabolic disruption that PMOS drives
- Culturally competent care, especially for Black and Brown women who have historically been underdiagnosed and undersupported
You should not have to self-diagnose through late-night internet searches. You should not have to convince a provider that what you are experiencing is real. And you should never leave an appointment feeling more confused and dismissed than when you arrived.
If you are a provider who believes in this kind of whole-person, equity-centered care, we want you on our team. mydiversehealth.com/join-our-team
If you have been living with unexplained symptoms, this is your sign
If you have ever been told your labs look “mostly fine” while you still feel completely off, this is for you. If your periods have never been regular, if your weight shifts in ways that make no sense to you, if you are exhausted in ways sleep does not fix, if your mental health dips and surges alongside your cycle, you deserve a provider who does not just run the same basic panel and send you home.
PMOS is a real, complex, multi-system condition. It is not in your head. It is not about willpower. And it is not something you manage alone.
The renaming is a beginning. Better care is what comes next.
References
- Polyendocrine Metabolic Ovarian Syndrome — The New Name for Polycystic Ovary Syndrome: A Multistep Global Consensus Process
https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(26)00717-8/fulltext
2. Polyendocrine Metabolic Ovarian Syndrome: New Name to Improve Diagnosis and Care of Condition Affecting 170 Million Women Worldwide
https://www.endocrine.org/news-and-advocacy/news-room/2026/pcos-name-change
https://www.statnews.com/2026/05/12/pcos-now-called-pmos-polyendocrine-metabolic-ovarian-syndrome/